Abstract Introduction: Anaphylaxis is a life-threatening allergic reaction which requires prompt medical treatment. Adrenaline auto-injectors (AAIs) can be self-administered to prevent worsening of anaphylactic symptoms. All patients must receive treatment and training in line with the national guidelines.
Aims: National guidance emphasises appropriate prescribing, clear documentation of indication, provision of two in-date devices, correct dosing and specialist referral. This audit evaluates adherence to these standards in paediatric patients within primary care.
Methods: A retrospective search of EMIS was undertaken. Patients aged under 16 who had been prescribed an AAI within the previous 12 months were included; those no longer registered with the practice were excluded. Eight patients met the inclusion criteria. Outcomes were compared against a 100% compliance standard for all criteria.
Results: All patients had a documented indication, appropriate dosing, and evidence of specialist referral. Seven patients (87.5%) were prescribed at least two in-date AAIs. No AAIs were initiated in primary care. Weight documentation was variable, with 5/8 patients (62.5%) having a recorded weight within one year of prescription, while 2/8 (25%) had no recorded weight. One patient (12.5%) was lost to follow-up and had no active AAI despite clinical risk. Only one patient (12.5%) was re-trained on their AAI once prescribed by secondary care.
Conclusions: Overall, this audit demonstrates a high adherence to anaphylactic management standards, particularly meeting indication criteria, dosing and specialist referral. However, gaps remain in weight documentation and patient follow-up. Improvements should focus on systematic weight monitoring, an annual AAI review with the pharmacist, and consideration of interim AAI prescribing in primary care to optimise patient safety. A re-audit has been scheduled for 3 months.

